share_log

Longeveron Receives FDA Fast Track Designation For Lomecel-B For Mild Alzheimer's Disease; Second Designation Following RMAT Designation On July 9, 2024

Benzinga ·  Jul 17 08:01

Phase 2a Data To Be Presented At Alzheimer's Association International Conference; Lomecel-B Is An Allogeneic Investigational Cellular Therapy Also Evaluated For Aging-Related Frailty And Hypoplastic Left Heart Syndrome

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment